OSMUNDA: Closes RMB 100 Million Series D Led Exclusively by Lishui Green Valley Talent Osmunda New Fund
NewTimeSpace News: Recently, Guangzhou Osmunda Medical Device Technology, Inc. (OSMUNDA), whose shares were formerly quoted on the National Equities Exchange and Quotations under code 835575 and were delisted on 2 March 2018, completed a RMB 100 million Series D round invested exclusively by the Lishui Green Valley Talent Osmunda New Fund. The post-money valuation was not disclosed. Proceeds will mainly fund the headquarters' MAH mass production plant, a provincial medical device proof-of-concept centre and pilot workshop, a global medical device AI digital platform, and the development and application of vertical large language models and industrial AI agents for the medical device sector. The news was disclosed on 13 November 2026.
OSMUNDA was founded in February 2004 by Dr. Zhang Feng, an international medical device regulatory expert, and Ms. Pan Wei, a senior expert in medical device investment, financing and resource integration. The company describes itself as China's first one-stop comprehensive medical device CXO platform, with a CRDMO platform spanning design, clinical registration and contract manufacturing, and a "3C" service model combining CRO, CDMO and CMD. It is an approved entity for formulating and reviewing export standards on the Ministry of Commerce white list, a strategic partner of Huawei, and has been recognised as one of the top 10 medical device CROs in Europe.
By the company's account, OSMUNDA has served more than 5,000 medical device clients worldwide, including 70% of China's listed medical device companies and 40% of the global Fortune 500 medical device companies, and has helped convert more than 3,600 new medical devices, supporting clients in obtaining over 2,500 NMPA registration certificates, more than 300 FDA registrations and over 800 CE certifications. Its self-developed vertical model OSMED covers idea generation and conversion assessment at the front end, compliance management from proof of concept to global registration in the middle, and volume production, global sales and post-market surveillance at the back end.
The investing fund was jointly initiated by Zhejiang Xietong Innovation Investment Management Co., Ltd. (浙江协同) and the Lishui Green Industry Development Fund, among others; Luo Yu, who leads the fund, cited the company's scarcity value as key infrastructure for the medical device industry. On the industry side, research cited by vbdata shows that CXO penetration in China's medical device sector remains below 10%, against a global average of about 20%, while 76 innovative medical devices were approved in China in 2025, up 17% year on year.
- EDDING GENOR (06998.HK): GB268 Wins NMPA Nod for NSCLC, BTC Trials
- HENLIUS (02696.HK): NMPA Clears HLX105 Phase 1 Solid Tumour IND
- KLIGHT LASER: Closes New Round Led by China Fortune-Tech Capital, Expanding Deep-Ultraviolet Output
- INNOVENT BIO (01801.HK): Sintilimab Gets First CHMP Positive Opinion for First-Line NSCLC
- EVEREST MED (01952.HK): Two Products Enter 2026 National Reimbursement List